Soyi Liu-Léage

524 total citations
21 papers, 404 citations indexed

About

Soyi Liu-Léage is a scholar working on Rheumatology, Orthopedics and Sports Medicine and Immunology. According to data from OpenAlex, Soyi Liu-Léage has authored 21 papers receiving a total of 404 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Rheumatology, 8 papers in Orthopedics and Sports Medicine and 8 papers in Immunology. Recurrent topics in Soyi Liu-Léage's work include Bone health and osteoporosis research (8 papers), Psoriasis: Treatment and Pathogenesis (7 papers) and Spondyloarthritis Studies and Treatments (7 papers). Soyi Liu-Léage is often cited by papers focused on Bone health and osteoporosis research (8 papers), Psoriasis: Treatment and Pathogenesis (7 papers) and Spondyloarthritis Studies and Treatments (7 papers). Soyi Liu-Léage collaborates with scholars based in France, United States and United Kingdom. Soyi Liu-Léage's co-authors include Christian Roux, Karine Briot, J. Fechtenbaum, B. Augendre‐Ferrante, Christophe Sapin, M. Wong, Patrick Garnero, E. Paris, Michael W. Draper and P. J. Meunier and has published in prestigious journals such as Annals of the Rheumatic Diseases, Bone and Osteoporosis International.

In The Last Decade

Soyi Liu-Léage

18 papers receiving 391 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Soyi Liu-Léage France 10 205 115 96 80 77 21 404
Bensen Wg Canada 9 181 0.9× 131 1.1× 81 0.8× 30 0.4× 96 1.2× 14 339
Christian Roux France 4 139 0.7× 77 0.7× 41 0.4× 15 0.2× 112 1.5× 7 296
Jialin Liang China 10 61 0.3× 28 0.2× 91 0.9× 20 0.3× 47 0.6× 19 272
E Boling United States 5 429 2.1× 299 2.6× 79 0.8× 21 0.3× 237 3.1× 7 590
Hye‐Rim Song South Korea 14 38 0.2× 85 0.7× 78 0.8× 15 0.2× 154 2.0× 31 418
Garth Beinart United States 6 255 1.2× 200 1.7× 10 0.1× 44 0.6× 151 2.0× 9 510
Mika Tsujimoto Japan 10 293 1.4× 227 2.0× 107 1.1× 8 0.1× 116 1.5× 16 471
Yingcai Ma China 4 137 0.7× 61 0.5× 13 0.1× 23 0.3× 108 1.4× 12 339
Delphine Stoll Switzerland 13 517 2.5× 419 3.6× 34 0.4× 11 0.1× 243 3.2× 45 698
R Rapisarda Italy 9 77 0.4× 41 0.4× 11 0.1× 18 0.2× 81 1.1× 26 287

Countries citing papers authored by Soyi Liu-Léage

Since Specialization
Citations

This map shows the geographic impact of Soyi Liu-Léage's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Soyi Liu-Léage with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Soyi Liu-Léage more than expected).

Fields of papers citing papers by Soyi Liu-Léage

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Soyi Liu-Léage. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Soyi Liu-Léage. The network helps show where Soyi Liu-Léage may publish in the future.

Co-authorship network of co-authors of Soyi Liu-Léage

This figure shows the co-authorship network connecting the top 25 collaborators of Soyi Liu-Léage. A scholar is included among the top collaborators of Soyi Liu-Léage based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Soyi Liu-Léage. Soyi Liu-Léage is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rudwaleit, Martín, Victoria Navarro‐Compán, Soyi Liu-Léage, et al.. (2025). BASDAI and ASDAS disease states in relationship to ASAS40 response: post hoc analysis of ixekizumab in radiographic axial spondyloarthritis. Rheumatology Advances in Practice. 9(2). rkaf012–rkaf012.
2.
Ramiro, Sofía, Cédric Lukas, Louis Bessette, et al.. (2024). Early clinical response associates with long-term outcomes with ixekizumab in radiographic axial spondyloarthritis. RMD Open. 10(3). e004429–e004429.
3.
Ramiro, Sofía, Cédric Lukas, Michael J. Nissen, et al.. (2024). Improvement in spinal pain at night and its impact on long-term outcomes in radiographic axial spondyloarthritis: Results from Ixekizumab COAST-V randomised trial. Seminars in Arthritis and Rheumatism. 69. 152571–152571. 1 indexed citations
4.
5.
Ruyssen‐Witrand, Adeline, et al.. (2020). Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis. RMD Open. 6(1). e001117–e001117. 59 indexed citations
6.
Smolen, Josef S, Anthony Sebba, Eric Ruderman, et al.. (2020). Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study. Rheumatology and Therapy. 7(4). 1021–1035. 27 indexed citations
7.
Smolen, Josef S, Peter Nash, Hasan Tahir, et al.. (2019). A Head-to-Head Comparison of Ixekizumab and Adalimumab in Biologic-Naive Patients with Active Psoriatic Arthritis: Efficacy and Safety Outcomes from a Randomized, Open-Label, Blinded Assessor Study Through 52 Weeks. Queensland's institutional digital repository (The University of Queensland). 71. 5266–5267. 1 indexed citations
8.
Hartz, S C, et al.. (2014). Elicitation of Health State Utilities Associated with Varying Severities of Flare in Systemic Lupus Erythematosus. Value in Health. 17(7). A331–A331. 1 indexed citations
9.
10.
Paintaud, Gilles, Marine Diviné, Philippe Lechat, et al.. (2012). Anticorps monoclonaux à usage thérapeutique : spécificités du développement clinique, évaluation par les agences, suivi de la tolérance à long terme. Therapies. 67(4). 319–327. 2 indexed citations
11.
Paintaud, Gilles, Marine Diviné, Philippe Lechat, et al.. (2012). Monoclonal Antibodies for Therapeutic Use: Specific Characteristics of Clinical Development, Evaluation by the Agencies, and Long-term Monitoring of Safety. Therapies. 67(4). 329–337. 2 indexed citations
12.
13.
Blumsohn, Aubrey, Fernando Marín, Thomas Nickélsen, et al.. (2010). Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide. Osteoporosis International. 22(6). 1935–1946. 56 indexed citations
14.
15.
Briot, Karine, et al.. (2008). Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience. Osteoporosis International. 20(4). 625–630. 44 indexed citations
16.
Roux, C., J. Fechtenbaum, Karine Briot, et al.. (2007). Inverse relationship between vertebral fractures and spine osteoarthritis in postmenopausal women with osteoporosis. Annals of the Rheumatic Diseases. 67(2). 224–228. 36 indexed citations
17.
Roux, Christian, et al.. (2006). A clinical tool to determine the necessity of spine radiography in postmenopausal women with osteoporosis presenting with back pain. Annals of the Rheumatic Diseases. 66(1). 81–85. 35 indexed citations
18.
Neven, Patrick, Deborah Quail, Fernando Marín, et al.. (2005). Comparing raloxifene with continuous combined estrogen–progestin therapy in postmenopausal women: Review of Euralox 1. Maturitas. 52(2). 87–101. 12 indexed citations
19.
Meunier, P. J., Patrick Garnero, E. Paris, et al.. (1999). Treatment of Postmenopausal Women with Osteoporosis or Low Bone Density with Raloxifene. Osteoporosis International. 10(4). 330–336. 80 indexed citations
20.
Agnusdei, D., Soyi Liu-Léage, & B. Augendre‐Ferrante. (1999). [Results of international clinical trials with raloxifene].. PubMed. 60(3). 242–6. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bensen Wg Breakdown of academic impact, for papers by Christian Roux Breakdown of academic impact, for papers by Jialin Liang Breakdown of academic impact, for papers by E Boling Breakdown of academic impact, for papers by Hye‐Rim Song Breakdown of academic impact, for papers by Garth Beinart Breakdown of academic impact, for papers by Mika Tsujimoto Breakdown of academic impact, for papers by Yingcai Ma Breakdown of academic impact, for papers by Delphine Stoll Breakdown of academic impact, for papers by R Rapisarda
Rankless by CCL
2026